Global Markets for In Vitro Toxicity Testing

Published - Sep 2010| Analyst - Paul Evers| Code - PHM017D
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

  • The global in vitro toxicity (predictive toxicity) testing market is valued at more than $1.3 billion in 2010.  With heightened awareness of animal welfare in laboratory research testing, the in vitro toxicity testing market has an anticipated value of $2.7 billion in 2015, a compound annual growth rate (CAGR) of 15% between 2010 and 2015.
  • The largest market sector is currently the cosmetics and personal-care industry, which accounts for a market share of more than 50%. This sector is currently valued at $702 million and is expected to reach $1.3 billion by 2015, a compound annual growth rate (CAGR) of 13.1%.
  • The pharmaceuticals segment is one of the most significant with a 32% market share valued at $424 million in 2010. By 2015, this sector is projected to reach a value of $976 million, a compound annual growth rate (CAGR) of 18.2%.


BCC’s goal in conducting this study was to determine the current status of the global in vitro toxicity testing market and assess its growth potential over the 5-year period from 2010 to 2015. We were particularly interested in understanding the current market scenario for alternative measures to animal testing.
Predictive toxicology is often cross-referenced with in vitro methods. This report assesses the growth and market potential for these methods. In addition, we were interested in understanding the impact of these methods on different industry sectors.
One key objective was to present an analysis of the current in vitro toxicity testing market in major national markets and its future direction.
Classical toxicology testing programs have been in place for many decades now. Over the past 2 decades, ongoing animal welfare activities have spurred the idea of pursuing alternative testing measures in toxicity with minimal pain and suffering to animals. This report aims to identify the key advances in different test categories and the extent of validation by the regulatory authorities. We also were interested in identifying the impact of new technology advancements with possible toxicology applications and also examining their growth potential.
There are different industries that require toxicity testing of their products. Previously, there was broad coverage of these applications. As this market relies strongly on both technology and regulatory forces, this study was aimed to identify the relevance of current developments on pharmaceuticals, chemicals, food additives, cosmetics, and household products.
The study encompasses the major types of traditional toxicity testing methods and the in vitro techniques that have been under review of the Interagency Coordinating Committee for Validation of Alternative Methods (ICCVAM) test methods for toxicity. BCC discusses the two major technology based approaches, mechanistic and nonmechanistic, and determines current market status; examines impact on future markets; and presents forecasts of growth over the next 5 years. Technological issues, including the latest trends, are discussed. Other influential factors such as validation of these alternative measures for toxicity and toxicity testing strategies for chemicals, pesticides, and food additives have also been included. BCC also examines the regulatory role and the different federal and international agencies that play an active role in in vitro toxicology research.
This report is designed to satisfy the information needs of a wide variety of individuals involved in the toxicity marketplace, including company senior management executives seeking to base their strategic decisions on the latest insights into toxicology market forces and trends. It is also aimed at managers and executives in product research and development and particularly those responsible for bringing new products to market.
Both primary and secondary research methodologies were used in preparing this study. Primary research includes interviews with leading individuals in relevant companies and associations; primary sources of published data include research studies, company annual reports, and government publications. Secondary sources consist of literature searches, industry journals, and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically assessed by BCC.
Paul Evers has been involved in analyzing pharmaceutical markets for 20 years. He is the author of previous reports on leading-edge developments at the interface between Research and Development (R&D) and the marketplace. 
BCC offers an online information retrieval service. BCC’s home page, located at, enables readers to: 
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers.
The information developed in this report, is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is of a speculative in nature.  The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Note: Reports are discounted or included with certain Memberships. See Membership Options.
Published - Mar-2007| Analyst - Vanita Khetan| Code - PHM017C

Report Highlights

  • The U.S. in vitro toxicity (predictive toxicity) testing market has been valued at $765 million in 2006. At a compound annual growth rate (CAGR) of 14.4%, the total U.S. market will grow to reach $1.5 billion by 2011.
  • Mechanistic toxicology testing had the highest growth through the forecast period, with an estimated CAGR of 21.8%. This sector of the market will be worth $720 million by 2011.
  • Non-mechanistic toxicology testing was the larger of the two sectors in 2006. Even with a CAGR of 9.4%, it will still maintain the majority of the market at $780 million in 2011.
Published - Jun-2003| Analyst - Sam Brauer| Code - PHM017B

Report Highlights

  • The pharmaceutical industry accounts for more than 90% of the industry.
  • In vitro toxicology growth (12.4%/year) will be higher than pharmaceutical R& D.
  • The pharmaceutical market will reach about $18.58 billion by 2007.
  • All other markets will grow 8%/year to reach $103 milion.
  • Overall, in vitro toxicology markets will see an AAGR of 12.1%.


Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report